Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study.

Objective: To document changes in pulmonary arterial systolic pressure (PASP) in patients with SLE who have received CYC for any indication.

Methods: Twenty-four patients with SLE pulmonary arterial hypertension (PAH) with a PASP of >30 mmHg by transthoracic echocardiography received i.v.